Pre-analytics and standardization at ISLB 2026

Nov 7–9, 2026 Madrid, Spain ~700 attendees Website

32 organizations at ISLB 2026 present work in pre-analytics & standards, led by universities and research institutes. Between them they bring 61 presentations to the program. Most represented: University of Naples Federico II, Princess Margaret Cancer Centre and CIMA University of Navarra. As of Oct 16, 2026.

All 160 organizations at ISLB 2026 →

Showing 1–8 of 32 organizations

Organization	ISLB 2026 Attendance
University of Naples Federico II Naples, Italy
unina.it Universities & research institutes Public university in Naples, Italy, with a school of medicine and a teaching hospital.	Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Collaborators: Universidad Politécnica de Madrid Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors From Diagnosis to Disease Monitoring: The Expanding Role of Liquid Biopsy Across Solid Tumours Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Industry Sun Nov 8 8:15am–9:15am Part of Enabling Precision Oncology: The Expanding Role of Liquid Biopsy Across Solid Tumors Panel Discussion and Q&A Industry hosted by AstraZeneca and Thermo Fisher Scientific Clinical use Session Sun Nov 8 9:30am–11:00am Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures New analytes Talk Sun Nov 8 9:30am–11:00am Part of Next-Generation Liquid Biopsy: RNA, Proteomics, and Exposome Signatures Proteomics in Liquid Biopsy: The Future is Here? New analytes Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Opening and Introduction Industry hosted by Menarini Stemline Clinical use · Pre-analytics Industry Sun Nov 8 12:15pm–1:15pm Part of ESR1 Testing in Liquid Biopsy: From Laboratory Excellence to Confident Clinical Decisions Clinical Cases Panel Discussion and Q&A Industry hosted by Menarini Stemline Clinical use · Pre-analytics Session Sun Nov 8 3:45pm–5:15pm Awards Lecture Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session The Evolving Landscape of Next-generation Sequencing in Liquid Biopsy Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Welcome, Framing, and Objectives Industry hosted by Guardant Health Clinical use · ctDNA & MRD Industry Mon Nov 9 8:00am–9:00am Part of From Plasma to Practice: Longitudinal Insights for Breast and Lung Cancer Panel Discussion & Live Q&A: What Makes a Longitudinal Liquid-Biopsy Result Actionable? Industry hosted by Guardant Health Clinical use · ctDNA & MRD Talk Mon Nov 9 10:00am–11:30am Part of Preferred Oral Abstract Session Identifying Educational Needs to Support Personalized Medicine Approaches in Cancer (SPARC): Preliminary Results from the Work Package 6 Survey Poster Part of Poster sessions Technical Feasibility of a Digital Solid PCR Platform Multiplexing ESR1 Activating Mutation in Real-world Liquid Biopsy Samples ctDNA & MRD · New analytes Collaborators: QIAGEN
Princess Margaret Cancer Centre Toronto, Canada
uhn.ca Hospitals & cancer centres Cancer centre of University Health Network in Toronto, for cancer care, research and education.	Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sun Nov 8 1:30pm–3:00pm Tumor Type Related Clinical use Talk Sun Nov 8 1:30pm–3:00pm Part of Tumor Type Related Multimodal Assays in HN/Perspectives from Radiation Oncology Clinical use Talk Sun Nov 8 3:45pm–5:15pm Part of Awards Lecture One Drop at a Time – Integrating Liquid Biopsy into Routine Practice Poster Part of Poster sessions Cell-free DNA Hydroxymethylation Profiling in Treatment-naive and Relapsed SCLC ctDNA & MRD Poster Part of Poster sessions Bronchoalveolar Lavage to Accelerate Time to Molecular Diagnosis in Early-stage Lung Cancer Pre-analytics · Clinical use
CIMA University of Navarra Pamplona, Spain
cima.cun.es Universities & research institutes Applied medical research centre of the University of Navarra, with a solid tumours programme.	Talk Sat Nov 7 9:45am–11:15am Part of Evolving and Future Methodologies in Liquid Biopsy: CTCs, Tumor Vesicles and Emerging Approaches Multimodal Liquid Biopsy in SCLC New analytes Session Sat Nov 7 1:45pm–3:15pm Stakeholder Workshop Session Sat Nov 7 4:00pm–5:30pm Workshop Biological Fluids: Pre-analytical Issues Pre-analytics Poster Part of Poster sessions Novel Cytokine-based Liquid Biopsy Biomarkers Related to Response and Survival in SCLC Patients Treated with Chemoimmunotherapy Clinical use · New analytes
University of Minnesota Minneapolis, MN
umn.edu Universities & research institutes Public research university in Minneapolis and Saint Paul, Minnesota, with medical and veterinary schools.	Poster Part of Poster sessions Single-cell Profiling of Liquid Biopsy Cells Associated with Cancer Risk Reveals Increased Inferred Copy Number Variation Early detection · New analytes Poster Part of Poster sessions Integration of the Shine on Suspicion Test and eBAT Interventional Therapy for Canine Cancer Prevention Early detection Poster Part of Poster sessions Disentangling Biological Signal from Technical Noise in Multi-matrix Cell-free DNA Profiling of Canine Diffuse Large B-cell Lymphoma Pre-analytics · ctDNA & MRD Poster Part of Poster sessions Test and Intervene: a Strategic Framework for Liquid Biopsy-guided Cancer Prevention Early detection
Natera Austin, TX	◇Bronze Sponsor
natera.com/oncology/signatera-advanced-cancer-detection Diagnostics & testing labsBronze Sponsor Offers Signatera, a personalized ctDNA test used to assess molecular residual disease and monitor treatment, validated in multiple cancer types.	Booth Exhibiting at Booth 29 Sat, Nov 710:00am–4:00pm, 6:00–7:30pmSun, Nov 810:00am–4:00pmMon, Nov 98:30am–10:30am Talk Sat Nov 7 3:15pm–4:00pm Part of Poster Tour Signatera Genome™ Assay for Enhanced ctDNA Detection in a Cohort of Patients (pts) with Solid Tumors Industry Mon Nov 9 9:00am–10:00am MRD Testing: Liquid Biopsy Reimagined for Real-Time Disease Monitoring ctDNA & MRD Poster Part of Poster sessions Budget Impact of Circulating Tumor DNA-guided Decisions in Post-radical Cystectomy High-risk Muscle-invasive Bladder Cancer in the United Kingdom Pre-analytics · ctDNA & MRD
GENYO Granada, Spain
genyo.es Universities & research institutes Genomics and oncology research centre run jointly by Pfizer, the University of Granada and the Andalusian regional government.	Talk Sun Nov 8 5:30pm–6:30pm Part of Young Career Session Summary of ISLB YC 2026 Activities Poster Part of Poster sessions Dynamic Circulating Tumour Cell Phenotypes and Circulating Tumour DNA Evolution During PARP Inhibitor Therapy in High-grade Serous Ovarian Cancer New analytes · ctDNA & MRD Poster Part of Poster sessions Comparative Evaluation of two Automated Magnetic-bead cell free DNA Extraction Workflows in Early Colorectal Cancer Pre-analytics
IRCCS Ospedale Policlinico San Martino Genoa, Italy
ospedalesanmartino.it Hospitals & cancer centres Public research hospital in Genoa and teaching hospital of the University of Genoa.	Poster Part of Poster sessions Clonal Hematopoiesis in Early Breast Cancer: A Pilot Study on Treatment Toxicity and Clinical Outcomes Clinical use Collaborators: Fondazione Edo ed Elvo Tempia Poster Part of Poster sessions Plasma and Pleural Effusion Profiling Reveals Histotype-related Immune Patterns in Pleural Mesothelioma Clinical use · Pre-analytics Poster Part of Poster sessions Role of Soluble TIM3 in Developing Acquired Resistance in Metastatic Non-small-cell Lung Cancer Patients Undergoing First-line Immune Checkpoint Inhibitor-based Therapy Clinical use · New analytes
Vall d'Hebron University Hospital Barcelona, Spain
vallhebron.com Hospitals & cancer centres Public university hospital in Barcelona, Spain, whose campus includes the Vall d'Hebron Institute of Oncology.	Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors When Tissue Falls Short: The Case for ctDNA in Detecting Emergent Resistance Mutations Industry hosted by MSD Clinical use · ctDNA & MRD Industry Sat Nov 7 12:30pm–1:30pm Part of Beyond Complementarity: Moving to Frontline ctDNA Decision-making in Solid Tumors Bringing ctDNA into Routine Care: Lessons from mCRPC Industry hosted by MSD Clinical use · ctDNA & MRD Poster Part of Poster sessions Harmonizing Plasma ESR1 Testing Across Spain: Results from the First Nationwide Multicenter Comparison of Commercial PCR Assays Pre-analytics Collaborators: Hospital del Mar